Radioimmunotherapy (RIT)

Radio immunotherapy (RIT) is a combination of radiation therapy and immunotherapy used to treat non-Hodgkin B-cell lymphoma and other types of cancer. RIT uses engineered monoclonal antibodies paired with radioactive materials called radiotracers. When injected into the patient’s bloodstream, they bind to cancer cells and deliver a high dose of radiation directly to the tumor. In RIT, a monoclonal antibody is paired with a radioactive material, or radiotracer. When injected into the patient’s bloodstream, the radiation-linked monoclonal antibody, or agent, travels to and binds to cancer cells, allowing a high dose of radiation to be delivered directly to the tumor.

 

    Related Conference of Radioimmunotherapy (RIT)

    March 26-27, 2026

    4th Global Virtual Summit on Radiology and Oncology

    Paris, France

    Radioimmunotherapy (RIT) Conference Speakers